AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 22 Sep - Company to attend PL Capital investor conference on September 29, 2026 in Mumbai.
Source: Bse
Nephrocare Health Services Limited (NEPHROPLUS)
Small CapPharma stocks · Small cap · NSE
Nephrocare Health Services Limited operates in Dialysis, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:15 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
60BullishSMA20 -7.9% / mo · RSI oversold · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 34
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
NEPHROPLUSD candles · FIT view+14.6%Latest close ₹611.55 on 2026-10-19
Daily history is available from 2025-12-17; the requested 1Y window is partially covered.
Bar
-0.1%
RSI
29
MACD hist
-3.83
52W pos
49%
2026-10-19O ₹612.00H ₹618.80L ₹603.60C ₹611.55Vol 1.5L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
NEPHROPLUSNifty PharmaNifty 500
- NEPHROPLUS
- -2.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +2.8 pp
Chart stats
19 Oct 2026- From 52W high
- -21.7%
- 52W range position
- 49%
- ATR (14)
- 3.4%
- Volume vs 20D
- 0.22x
- Avg traded value
- ₹48.8 Cr
- 20D price channel
- ₹601.1 - ₹762.1
₹781.5
₹446 - ₹781.5
₹21
Latest completed session
20-session average
22.4% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST40
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good67
Revenue +23.7% · PAT +33.3% YoY
Technical
Bullish60
Price trend and sector-relative-strength timing.
Valuation
Legacy model-224.3%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence73
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 67/100Rev +24% YoY · PAT +33% YoY · +6% QoQ · operating leverage · margin compression
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹282 Cr | +23.7% | +6.0% |
| EBITDA | ₹60 Cr | +25.0% | +17.6% |
| Operating margin | 21.0% | +0 bps | +200 bps |
| PAT | ₹32 Cr | +33.3% | +6.7% |
| PAT margin | 11.3% | +82 bps | +7 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 75.60
- P/B
- 5.75
- EV/EBITDA
- 19.61
- Market Cap
- 6431.00Cr
Profitability
- ROE
- 8.83%
- ROCE
- 15.30%
- ROA
- 5.79%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 28.00%
- EPS 5Y
- 162.00%
- Revenue 3Y
- 32.00%
- EPS 3Y
- 103.00%
Balance Sheet
- Debt/Equity
- 0.07
- Interest Coverage
- 4.21×
- Altman Z
- 8.57
- Book Value
- 111.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 2/5
- OCF
- 233.00 Cr
- EPS TTM
- 4.19
Shareholding
- Promoter Hold
- 63.85%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 57%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 999+32.1% vs prev
Net Profit
₹ CrLatest: 77.0+14.9% vs prev
Return on Equity
%Latest: 6.9-40.2% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 29. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~8.5% over last month) — short-term momentum negative.
- RSI(14) at 29 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- 22% off 52W high · 37% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
69
RS percentile
Stage 1 Base / Transition
1M return
-17.7%
3M return
-2.7%
6M return
+10.7%
1Y return
-
RS 1D
+3
RS 20D
-7
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is within 4.6% of the 30-week proxy.
- The 30-week proxy changed +2.0% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
207 observations
19 Oct 2026Value 138.34+0.58%
RS vs Nifty 500138
Valuation & peers
U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 40 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth20/25
Quality3/20
Balance Sheet10/15
Cash Flow2/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
40
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
40/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Growth contributes 20/25 to the score.
- Balance sheet contributes 10/15 to the score.
Main drags
- Fair-value margin of safety is negative at -224.3%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Quality is weaker at 3/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
75.6
PB
5.8
EV/EBITDA
19.6
ROE
8.8%
ROCE
15.3%
FCF Yield
—
Debt/Equity
0.1
MoS
-224.3%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
40
Previous: 40
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-224.3%
Previous: -224.3%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
40
40
40
40
40
40
40
40
40
40
40
40
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹102.3
-497.8% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹188.55
-224.3% MoS
PEG
0.55
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
NEPHROCARE
SME
Nephro Care India Ltd.
Healthcare Services
match 150
14
27.7
4.9%
-464%
OVERVALUED
KOVAI
Small
Kovai Medical Center & Hospital Limited
Healthcare Services
match 139
46
113.0
22.2%
-146%
FAIR VALUE
SENORES
Small
Senores Pharmaceuticals Limited
Healthcare Services
match 139
35
48.2
13.4%
-2%
WATCHLIST
ORCHPHARMA
Small
Orchid Pharma Limited
Healthcare Services
match 138
33
320.0
1.5%
-846%
WATCHLIST
ARTEMISMED
Small
Artemis Medicare Services Limited
Healthcare Services
match 138
39
44.2
12.0%
+10%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Nephrocare Health Services Limited operates in Dialysis, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
73Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 72nd percentile of the scored universe and 63rd percentile within Pharma. Main check: cash conversion is weak at 55/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
20 docs text-extracted · 4 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
72nd percentile
overall median 67 · Pharma: 63rd pctile, median 70 · Small: 75th pctile, median 66
Evidence depth
Financial-only
20 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
76
strong · capital discipline
Results
63
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 63.9%.
- ▸Promoter pledge is zero.
- ▸Debt/equity is 0.07.
- ▸Latest 3 quarters had positive YoY PAT growth.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Nephrocare Health Services Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Restructuring 18 Sep - Board approved consolidation of Philippines step-down subsidiaries on September 18, 2026.
Source: Bse
Credit ratingSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Credit Rating 18 Sep - India Ratings upgrades bank loan facilities to IND AA-/Stable and affirms short-term IND A1+ on Sept. 18, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Acquisition 1 Sep - NPHSK LLP to acquire 100% of Dialysis Center Almaty LLP for KZT 561.66 million.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Updates on Acquisition 12 Aug - Clarifies NPHSK LLP in Kazakhstan is a step-down subsidiary, with 99% held by NHSI.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 17 Jul - Newspaper Publication regarding Notice on 17th Annual General Meeting and information on remote e-voting.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Jul - Newspaper publication titled 17th Annual General Meeting of the Company through Video conferencing / Other Audio Visual Means, Cut-Off date information.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 25 Jun - Overseas subsidiary acquires dialysis center assets in Orion, Bataan for PhP 151.6 million.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Jun - The Company has scheduled an Investor Conference Call as per the disclosure enclosed herewith.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements 4 Jun - Step-down subsidiary acquired dialysis center assets in Quezon City, Philippines for PHP 30 million.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 May
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 May
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.